EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer
6 August 2014 | By Roche
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer...
List view / Grid view
News
Merck publishes 2013 global corporate responsibility report
6 August 2014 | By Merck
Merck issued its 2013 global corporate responsibility report...
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
Merck completes tender offer to acquire Idenix
5 August 2014 | By Merck
Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share...
Boehringer Ingelheim receives two FDA approvals
4 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.
Amgen announces Phase 3 ASPIRE trial of Kyprolis® in patients with relapsed multiple myeloma met primary endpoint
4 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival...
European Medicines Agency looks to stimulate better use of genomic data and biomarkers in medicines development and safety monitoring
4 August 2014 | By The European Medicines Agency
The European Medicines Agency has released a draft concept paper for public consultation outlining the key elements that will be developed in a guideline on good genomics biomarker practices...
Allied Minds and Bristol-Myers Squibb form new enterprise to advance discoveries of biopharmaceutical innovations at leading U.S. academic research
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations...
AbbVie receives EMA and FDA orphan drug designation for investigational compound ABT-414 in the treatment of Glioblastoma multiforme
4 August 2014 | By AbbVie
AbbVie announced the European Medicines Agency and the U.S. Food and Drug Administration have granted orphan drug designation to AbbVie's investigational compound ABT-414...
Alcon’s Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease
4 August 2014 | By Novartis
Alcon announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission to decrease elevated intraocular pressure...
European Medicines Agency invites comments on new overarching guidance for the development of influenza vaccines
31 July 2014 | By The European Medicines Agency
The European Medicines Agency has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation...
KAE609 shows promise as next generation treatment for malaria
31 July 2014 | By Novartis
Novartis published clinical trial results in the New England Journal of Medicine showing that KAE609 (cipargamin), a novel and potent antimalarial drug candidate...
Pfizer enters into agreement to acquire Baxter’s portfolio of marketed vaccines
30 July 2014 | By Pfizer
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million...
CHMP issues positive opinion for intravenous formulation of Merck’s NOXAFIL® (posaconazole)
30 July 2014 | By Merck
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a new, investigational intravenous formulation of NOXAFIL® (posaconazole)...
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
30 July 2014 | By AstraZeneca
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion...
